New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

abstract：Background:Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective:To p...

journal_title：Therapeutic advances in neurological disorders

authors： Gklinos P,Mitsikostas DD

更新日期：2020-04-28 00:00:00

abstract：OBJECTIVES:The cumulative safety and efficacy measures of percutaneous transluminal angioplasty and stenting (PTAS) for secondary stroke prevention in patients with symptomatic intracranial arterial stenosis (sICAS) have not previously been evaluated using a meta-analytical approach. METHODS:We conducted a systematic ...

journal_title：Therapeutic advances in neurological disorders

authors： Tsivgoulis G,Katsanos AH,Magoufis G,Kargiotis O,Papadimitropoulos G,Vadikolias K,Karapanayiotides T,Ellul J,Alexandrov AW,Mitsias PD,Alexandrov AV

更新日期：2016-09-01 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：BACKGROUND:Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogen...

journal_title：Therapeutic advances in neurological disorders

authors： White JT,Newsome SD,Kieseier BC,Bermel RA,Cui Y,Seddighzadeh A,Hung S,Crossman M,Subramanyam M

更新日期：2016-07-01 00:00:00

abstract：:Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

journal_title：Therapeutic advances in neurological disorders

authors： Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

更新日期：2012-07-01 00:00:00

abstract：:Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

journal_title：Therapeutic advances in neurological disorders

authors： Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

更新日期：2010-05-01 00:00:00

abstract：:Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

journal_title：Therapeutic advances in neurological disorders

authors： Cortese R,Collorone S,Ciccarelli O,Toosy AT

更新日期：2019-06-27 00:00:00

abstract：Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

journal_title：Therapeutic advances in neurological disorders

authors： Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

更新日期：2020-07-30 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00

abstract：:Brain atrophy, white matter abnormalities, and ventricular enlargement have been described in different neuromuscular diseases (NMDs). We aimed to provide a comprehensive overview of the substantial advancement of brain imaging in neuromuscular diseases by consulting the main libraries (Pubmed, Scopus and Google Schol...

journal_title：Therapeutic advances in neurological disorders

authors： Angelini C,Pinzan E

更新日期：2019-05-06 00:00:00

abstract：:Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

journal_title：Therapeutic advances in neurological disorders

authors： Haussleiter IS,Brüne M,Juckel G

更新日期：2009-01-01 00:00:00

abstract：Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

journal_title：Therapeutic advances in neurological disorders

authors： Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

更新日期：2020-08-10 00:00:00

abstract：:Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

journal_title：Therapeutic advances in neurological disorders

authors： Subirós N,Del Barco DG,Coro-Antich RM

更新日期：2012-05-01 00:00:00

abstract：:Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

journal_title：Therapeutic advances in neurological disorders

authors： Fernández O

更新日期：2013-03-01 00:00:00

abstract：Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

journal_title：Therapeutic advances in neurological disorders

authors： Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

更新日期：2019-12-02 00:00:00

abstract：Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

journal_title：Therapeutic advances in neurological disorders

authors： Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

更新日期：2019-04-24 00:00:00

abstract：:Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgro...

journal_title：Therapeutic advances in neurological disorders

authors： Safouris A,Triantafyllou N,Parissis J,Tsivgoulis G

更新日期：2015-11-01 00:00:00

abstract：:The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

journal_title：Therapeutic advances in neurological disorders

authors： Fischer S,Weber W

更新日期：2017-11-22 00:00:00

abstract：:Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials a...

journal_title：Therapeutic advances in neurological disorders

authors： Khatri BO

更新日期：2016-03-01 00:00:00

abstract：:Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

journal_title：Therapeutic advances in neurological disorders

authors： Araki M,Lin Y,Ono H,Sato W,Yamamura T

更新日期：2018-08-18 00:00:00

abstract：:Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS). Structurally related to linomide, its pharmacological predecessor, laquinimod combines anti-inflammatory and possibly clinically relevant neuroprotective effects with the convenience of ...

journal_title：Therapeutic advances in neurological disorders

authors： Haggiag S,Ruggieri S,Gasperini C

更新日期：2013-11-01 00:00:00

abstract：:Essential tremor (ET) is the most common adult movement disorder. Traditionally considered as a benign disease, it can cause an important physical and psychosocial disability. Drug treatment for ET remains poor and often unsatisfactory. Current therapeutic strategies for ET are reviewed according to the level of disco...

journal_title：Therapeutic advances in neurological disorders

authors： Gironell A,Kulisevsky J

更新日期：2009-07-01 00:00:00

abstract：Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

journal_title：Therapeutic advances in neurological disorders

authors： Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

更新日期：2018-08-28 00:00:00

abstract：:Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

journal_title：Therapeutic advances in neurological disorders

authors： Walker KG,Wilmshurst JM

更新日期：2010-09-01 00:00:00

abstract：:For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

journal_title：Therapeutic advances in neurological disorders

authors： Awad A,Stüve O

更新日期：2009-11-01 00:00:00

abstract：:Impulse control disorders are a psychiatric condition characterized by the failure to resist an impulsive act or behavior that may be harmful to self or others. In movement disorders, impulse control disorders are associated with dopaminergic treatment, notably dopamine agonists (DAs). Impulse control disorders have b...

journal_title：Therapeutic advances in neurological disorders

authors： Mestre TA,Strafella AP,Thomsen T,Voon V,Miyasaki J

更新日期：2013-05-01 00:00:00

abstract：:Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

journal_title：Therapeutic advances in neurological disorders

authors： Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

更新日期：2018-08-09 00:00:00

abstract：:The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

journal_title：Therapeutic advances in neurological disorders

authors： Tallner A,Pfeifer K,Mäurer M

更新日期：2016-07-01 00:00:00

abstract：:Blepharospasm is a focal (although usually bilateral) dystonia of the orbicularis oculi muscles, producing excessive eye closure. This produces significant disability through functional blindness. Botulinum neurotoxins (BoNT) have become the treatment of choice for blepharospasm; the impressive response rate and the t...

journal_title：Therapeutic advances in neurological disorders

authors： Hellman A,Torres-Russotto D

更新日期：2015-03-01 00:00:00

abstract：:In the past few years, acquired demyelinating syndromes of the central nervous system associated with antibodies against myelin oligodendrocyte glycoprotein (MOG) have evolved into a new inflammatory disease entity distinct from neuromyelitis optica spectrum disorders or multiple sclerosis. The meticulous clinical des...

journal_title：Therapeutic advances in neurological disorders

authors： Hegen H,Reindl M

更新日期：2020-07-31 00:00:00